Prevalence of common adverse events experienced following COVID‐19 vaccination and its associated factors in Ghana: Cross‐sectional study design
Abstract Background and Aims The novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) (COVID‐19) pandemic devasted the general life of people and various human activities across the globe, and Ghana is of no exception. This led to development of vaccines within record time to combat mo...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.1012 |
| _version_ | 1797737742203879424 |
|---|---|
| author | Naa A. A. Boi‐Dsane Bartholomew Dzudzor Yakubu Alhassan Justice M. K. Aheto |
| author_facet | Naa A. A. Boi‐Dsane Bartholomew Dzudzor Yakubu Alhassan Justice M. K. Aheto |
| author_sort | Naa A. A. Boi‐Dsane |
| collection | DOAJ |
| description | Abstract Background and Aims The novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) (COVID‐19) pandemic devasted the general life of people and various human activities across the globe, and Ghana is of no exception. This led to development of vaccines within record time to combat morbidity and mortality associated with the virus. In Ghana, COVID‐19 vaccines were introduced in addition to existing COVID‐19 protocols. However, the vaccines have adverse events among those who received them. In this study, we determined the prevalence of some common adverse events of the COVID‐19 vaccines and its associated sociodemographic factors in Ghana. Methods An online snowball cross‐sectional survey was conducted between April and June 2021 among 240 people who had taken at least one dose of any of the COVID‐19 vaccines approved in Ghana. The penalized binary logistic regression model was used to assess the factors associated with experience of at least one adverse event and the experience of number of adverse events using Stata version 16. Results Among the 240 participants, 88.2% had experienced at least one adverse event. The most common adverse event after the first dose was pain at injection site (65.8%), headache (57.5%), tiredness (55.8%), fever (51.7%), chills (39.6%), and muscle pains (38.3%). Experience of adverse events was 16 times higher among those who took their vaccines in Ghana (adjusted odd ratio [AOR]: 16.2, 95% confidence interval [CI]: 1.98–132.56, p = 0.009), 94% less among those who took AstraZeneca (India) compared to AstraZeneca (Oxford) (AOR: 0.06, 95% CI: 0.01–0.37, p = 0.002) and 86% less among 40–49 years compared with less than 30 years old (AOR: 0.14, 95% CI: 0.03–0.58, p = 0.007). Conclusion Pain at the injection site, headache, tiredness, fever, chills, and muscle pains were the most frequently reported adverse events. The study identified country of vaccination, country of origin of AstraZeneca vaccine and age to be associated with adverse events of vaccination. |
| first_indexed | 2024-03-12T13:33:48Z |
| format | Article |
| id | doaj.art-e24ea9f4e7534758b1e92cd6bf3752b0 |
| institution | Directory Open Access Journal |
| issn | 2398-8835 |
| language | English |
| last_indexed | 2024-03-12T13:33:48Z |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj.art-e24ea9f4e7534758b1e92cd6bf3752b02023-08-24T06:32:46ZengWileyHealth Science Reports2398-88352023-01-0161n/an/a10.1002/hsr2.1012Prevalence of common adverse events experienced following COVID‐19 vaccination and its associated factors in Ghana: Cross‐sectional study designNaa A. A. Boi‐Dsane0Bartholomew Dzudzor1Yakubu Alhassan2Justice M. K. Aheto3Department of Medical Biochemistry University of Ghana Medical School, Korle‐Bu, College of Health Sciences University of Ghana Accra GhanaDepartment of Medical Biochemistry University of Ghana Medical School, Korle‐Bu, College of Health Sciences University of Ghana Accra GhanaDepartment of Biostatistics School of Public Health, College of Health Sciences University of Ghana Accra GhanaDepartment of Biostatistics School of Public Health, College of Health Sciences University of Ghana Accra GhanaAbstract Background and Aims The novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) (COVID‐19) pandemic devasted the general life of people and various human activities across the globe, and Ghana is of no exception. This led to development of vaccines within record time to combat morbidity and mortality associated with the virus. In Ghana, COVID‐19 vaccines were introduced in addition to existing COVID‐19 protocols. However, the vaccines have adverse events among those who received them. In this study, we determined the prevalence of some common adverse events of the COVID‐19 vaccines and its associated sociodemographic factors in Ghana. Methods An online snowball cross‐sectional survey was conducted between April and June 2021 among 240 people who had taken at least one dose of any of the COVID‐19 vaccines approved in Ghana. The penalized binary logistic regression model was used to assess the factors associated with experience of at least one adverse event and the experience of number of adverse events using Stata version 16. Results Among the 240 participants, 88.2% had experienced at least one adverse event. The most common adverse event after the first dose was pain at injection site (65.8%), headache (57.5%), tiredness (55.8%), fever (51.7%), chills (39.6%), and muscle pains (38.3%). Experience of adverse events was 16 times higher among those who took their vaccines in Ghana (adjusted odd ratio [AOR]: 16.2, 95% confidence interval [CI]: 1.98–132.56, p = 0.009), 94% less among those who took AstraZeneca (India) compared to AstraZeneca (Oxford) (AOR: 0.06, 95% CI: 0.01–0.37, p = 0.002) and 86% less among 40–49 years compared with less than 30 years old (AOR: 0.14, 95% CI: 0.03–0.58, p = 0.007). Conclusion Pain at the injection site, headache, tiredness, fever, chills, and muscle pains were the most frequently reported adverse events. The study identified country of vaccination, country of origin of AstraZeneca vaccine and age to be associated with adverse events of vaccination.https://doi.org/10.1002/hsr2.1012adverse eventsadverse events predictorsCOVID‐19COVID‐19 diagnosisSARS‐CoV‐2vaccination |
| spellingShingle | Naa A. A. Boi‐Dsane Bartholomew Dzudzor Yakubu Alhassan Justice M. K. Aheto Prevalence of common adverse events experienced following COVID‐19 vaccination and its associated factors in Ghana: Cross‐sectional study design Health Science Reports adverse events adverse events predictors COVID‐19 COVID‐19 diagnosis SARS‐CoV‐2 vaccination |
| title | Prevalence of common adverse events experienced following COVID‐19 vaccination and its associated factors in Ghana: Cross‐sectional study design |
| title_full | Prevalence of common adverse events experienced following COVID‐19 vaccination and its associated factors in Ghana: Cross‐sectional study design |
| title_fullStr | Prevalence of common adverse events experienced following COVID‐19 vaccination and its associated factors in Ghana: Cross‐sectional study design |
| title_full_unstemmed | Prevalence of common adverse events experienced following COVID‐19 vaccination and its associated factors in Ghana: Cross‐sectional study design |
| title_short | Prevalence of common adverse events experienced following COVID‐19 vaccination and its associated factors in Ghana: Cross‐sectional study design |
| title_sort | prevalence of common adverse events experienced following covid 19 vaccination and its associated factors in ghana cross sectional study design |
| topic | adverse events adverse events predictors COVID‐19 COVID‐19 diagnosis SARS‐CoV‐2 vaccination |
| url | https://doi.org/10.1002/hsr2.1012 |
| work_keys_str_mv | AT naaaaboidsane prevalenceofcommonadverseeventsexperiencedfollowingcovid19vaccinationanditsassociatedfactorsinghanacrosssectionalstudydesign AT bartholomewdzudzor prevalenceofcommonadverseeventsexperiencedfollowingcovid19vaccinationanditsassociatedfactorsinghanacrosssectionalstudydesign AT yakubualhassan prevalenceofcommonadverseeventsexperiencedfollowingcovid19vaccinationanditsassociatedfactorsinghanacrosssectionalstudydesign AT justicemkaheto prevalenceofcommonadverseeventsexperiencedfollowingcovid19vaccinationanditsassociatedfactorsinghanacrosssectionalstudydesign |